118 related articles for article (PubMed ID: 35279875)
1. FAT1 and MSH2 Are Predictive Prognostic Markers for Chinese Osteosarcoma Patients Following Chemotherapeutic Treatment.
Zhou C; Sun Y; Gong Z; Li J; Zhao X; Yang Q; Yu H; Ye J; Liang J; Jiang L; Zhang D; Shen Z; Zheng S
J Bone Miner Res; 2022 May; 37(5):885-895. PubMed ID: 35279875
[TBL] [Abstract][Full Text] [Related]
2. Expression of MSH2 and MSH6 on a tissue microarray in patients with osteosarcoma.
Jentzsch T; Robl B; Husmann M; Bode-Lesniewska B; Fuchs B
Anticancer Res; 2014 Dec; 34(12):6961-72. PubMed ID: 25503122
[TBL] [Abstract][Full Text] [Related]
3. A First Step toward Personalized Medicine in Osteosarcoma: Pharmacogenetics as Predictive Marker of Outcome after Chemotherapy-Based Treatment.
Hagleitner MM; Coenen MJ; Gelderblom H; Makkinje RR; Vos HI; de Bont ES; van der Graaf WT; Schreuder HW; Flucke U; van Leeuwen FN; Hoogerbrugge PM; Guchelaar HJ; te Loo DM
Clin Cancer Res; 2015 Aug; 21(15):3436-41. PubMed ID: 25829401
[TBL] [Abstract][Full Text] [Related]
4. SDH mutations, as potential predictor of chemotherapy prognosis in small cell lung cancer patients.
Zeng R; Fan X; Yang J; Fang C; Li J; Wen W; Liu J; Lv M; Feng X; Zhao X; Yu H; Zhang Y; Sun X; Bao Z; Zhou J; Ni L; Wang X; Cheng Q; Gao B; Gong Z; Zhang D; Dong Y; Xiang Y
Discov Oncol; 2023 Jun; 14(1):89. PubMed ID: 37273084
[TBL] [Abstract][Full Text] [Related]
5. Expression profiles of osteosarcoma that can predict response to chemotherapy.
Man TK; Chintagumpala M; Visvanathan J; Shen J; Perlaky L; Hicks J; Johnson M; Davino N; Murray J; Helman L; Meyer W; Triche T; Wong KK; Lau CC
Cancer Res; 2005 Sep; 65(18):8142-50. PubMed ID: 16166288
[TBL] [Abstract][Full Text] [Related]
6. Molecular classification of osteosarcoma.
Lau CC
Cancer Treat Res; 2009; 152():459-65. PubMed ID: 20213408
[TBL] [Abstract][Full Text] [Related]
7. Individualized chemotherapy for osteosarcoma and identification of gene mutations in osteosarcoma.
Xiao X; Wang W; Zhang H; Gao P; Fan B; Huang C; Fu J; Chen G; Shi L; Zhu H; Li X; Li J; Fan H; Wu Z; Guo Z; Hu Y; Wu S; Yu X; Xu C; Wang Z
Tumour Biol; 2015 Apr; 36(4):2427-35. PubMed ID: 25431261
[TBL] [Abstract][Full Text] [Related]
8. Comprehensive analysis of prognostic tumor microenvironment-related genes in osteosarcoma patients.
Hu C; Liu C; Tian S; Wang Y; Shen R; Rao H; Li J; Yang X; Chen B; Ye L
BMC Cancer; 2020 Aug; 20(1):814. PubMed ID: 32854645
[TBL] [Abstract][Full Text] [Related]
9. Clinical and Molecular Analysis of Pathologic Fracture-associated Osteosarcoma: MicroRNA profile Is Different and Correlates with Prognosis.
Lozano Calderón SA; Garbutt C; Kim J; Lietz CE; Chen YL; Bernstein K; Chebib I; Nielsen GP; Deshpande V; Rubio R; Wang YE; Quackenbush J; Delaney T; Raskin K; Schwab J; Cote G; Spentzos D
Clin Orthop Relat Res; 2019 Sep; 477(9):2114-2126. PubMed ID: 31389890
[TBL] [Abstract][Full Text] [Related]
10. Singe nucleotide polymorphisms in osteosarcoma: Pathogenic effect and prognostic significance.
Asnafi AA; Behzad MM; Ghanavat M; Shahjahani M; Saki N
Exp Mol Pathol; 2019 Feb; 106():63-77. PubMed ID: 30528563
[TBL] [Abstract][Full Text] [Related]
11. SPARCL1, Shp2, MSH2, E-cadherin, p53, ADCY-2 and MAPK are prognosis-related in colorectal cancer.
Yu SJ; Yu JK; Ge WT; Hu HG; Yuan Y; Zheng S
World J Gastroenterol; 2011 Apr; 17(15):2028-36. PubMed ID: 21528083
[TBL] [Abstract][Full Text] [Related]
12. MAPK7 and MAP2K4 as prognostic markers in osteosarcoma.
Tesser-Gamba F; Petrilli AS; de Seixas Alves MT; Filho RJ; Juliano Y; Toledo SR
Hum Pathol; 2012 Jul; 43(7):994-1002. PubMed ID: 22154052
[TBL] [Abstract][Full Text] [Related]
13. Profiles of immune cell infiltration and immune-related genes in the tumor microenvironment of osteosarcoma cancer.
Liu R; Hu Y; Liu T; Wang Y
BMC Cancer; 2021 Dec; 21(1):1345. PubMed ID: 34922489
[TBL] [Abstract][Full Text] [Related]
14. The role of pharmacogenetics in the treatment of osteosarcoma.
Vos HI; Coenen MJ; Guchelaar HJ; Te Loo DM
Drug Discov Today; 2016 Nov; 21(11):1775-1786. PubMed ID: 27352631
[TBL] [Abstract][Full Text] [Related]
15. MAPK7 variants related to prognosis and chemotherapy response in osteosarcoma.
Tesser-Gamba F; Paolillo AT; Del Giúdice Paniago M; Petrilli AS; Seixas Alves MT; Garcia Filho RJ; Toledo SRC
Ann Diagn Pathol; 2020 Jun; 46():151482. PubMed ID: 32145682
[TBL] [Abstract][Full Text] [Related]
16. HER-2 expression in biopsy and surgical specimen on prognosis of osteosarcoma: A systematic review and meta-analysis of 16 studies.
Zhang Q; Liu F; Wang B; Li Z; Zhou D; Yang Q; Dong J; Li J
Medicine (Baltimore); 2016 Jun; 95(23):e3661. PubMed ID: 27281068
[TBL] [Abstract][Full Text] [Related]
17. Predictive potential of glutathione S-transferase polymorphisms for prognosis of osteosarcoma patients on chemotherapy.
Zhang SL; Mao NF; Sun JY; Shi ZC; Wang B; Sun YJ
Asian Pac J Cancer Prev; 2012; 13(6):2705-9. PubMed ID: 22938445
[TBL] [Abstract][Full Text] [Related]
18. Can pretreatment
Song H; Jiao Y; Wei W; Ren X; Shen C; Qiu Z; Yang Q; Wang Q; Luo QY
Eur Radiol; 2019 Jul; 29(7):3945-3954. PubMed ID: 30859285
[TBL] [Abstract][Full Text] [Related]
19. Identification of 9-Gene Epithelial-Mesenchymal Transition Related Signature of Osteosarcoma by Integrating Multi Cohorts.
Yiqi Z; Ziyun L; Qin F; Xingli W; Liyu Y
Technol Cancer Res Treat; 2020; 19():1533033820980769. PubMed ID: 33308057
[TBL] [Abstract][Full Text] [Related]
20. A novel classification predicts prognosis and drug sensitivity in osteosarcoma based on alterations in gene sets.
Ye S; Wang X; Chen R
Aging (Albany NY); 2024 Feb; 16(5):4579-4590. PubMed ID: 38428404
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
